Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

156
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

05/14/2012 | 12:55pm US/Eastern
Recommend:
0

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

 
   By Jennifer Corbett Dooren 
   Of  
 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Recommend :
0
React to this article
Latest news on NOVARTIS AG
9h ago For Roche CEO, celebrating failure is key to success
10h ago Court grants novartis temporary injunction against ranbaxy
14h ago NOVARTIS : to tackle climate change with Sichuan tree planting project
16h ago NOVARTIS : presents oncology research advances with new data on Zykadia(TM), Afi..
16h ago NOVARTIS : presents oncology research advances with new data on Zykadia(TM), Afi..
1d ago NOVARTIS : China Valsartan Hydrochlorothiazide Market Analysis & Forecast Resear..
1d ago NOVARTIS : Ari Gnanasakthy, Karoly Kulich Join RTI Health Solutions Adding Decad..
2d ago NOVARTIS : CONTRACT AWARD - 65-- Oxazepam Capsules Sandoz, Inc Effective: 9/22/2..
2d ago NOVARTIS : Health and Human Services Department (HHS); Food and Drug Administrat..
2d ago NESTLERFD : VGK, DUST: Big ETF Outflows
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
Novartis AG : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF